A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer

被引：24
|
作者：
Wainberg, Zev [1 ]
Hecht, J. Randolph [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, GI Oncol Program, Los Angeles, CA 90095 USA
来源：
CLINICAL COLORECTAL CANCER | 2006年 / 5卷 / 05期
关键词：
epidermal growth factor receptor; 5-fluorouracil; irinotecan; leucovorin; oxaliplatin; vascular endothelial growth factor;
D O I：
10.3816/CCC.2006.n.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：363 / 367
页数：5
相关论文
共 50 条
  • [1] AN OPEN-LABEL SAFETY STUDY OF FIRST-LINE BEVACIZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY IN CHINESE PATIENTS WITH METASTATIC COLORECTAL CANCER
    Lee, K.
    Chen, H.
    Wang, H.
    Tsao, C.
    Chiou, C.
    Hsu, T.
    Su, W.
    Wang, J.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [2] NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
    Rinaldi, Fiona
    George, Elisabeth
    Adler, Amanda I.
    [J]. LANCET ONCOLOGY, 2012, 13 (03): : 233 - 234
  • [3] S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial
    Yamada, Y.
    Denda, T.
    Gamoh, M.
    Iwanaga, I.
    Yuki, S.
    Shimodaira, H.
    Nakamura, M.
    Yamaguchi, T.
    Ohori, H.
    Kobayashi, K.
    Tsuda, M.
    Kobayashi, Y.
    Miyamoto, Y.
    Kotake, M.
    Shimada, K.
    Sato, A.
    Morita, S.
    Takahashi, S.
    Komatsu, Y.
    Ishioka, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 624 - 631
  • [4] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
  • [5] Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial
    Robert, Nicholas J.
    Saleh, Mansoor N.
    Paul, Devchand
    Generali, Daniele
    Gressot, Laurent
    Copur, Mehmet S.
    Brufsky, Adam M.
    Minton, Susan E.
    Giguere, Jeffrey K.
    Smith, John W., II
    Richards, Paul D.
    Gernhardt, Diana
    Huang, Xin
    Liau, Katherine F.
    Kern, Kenneth A.
    Davis, John
    [J]. CLINICAL BREAST CANCER, 2011, 11 (02) : 82 - 92
  • [6] A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Mitchell, Edith
    Chidiac, Tarek
    Scroggin, Carroll
    Hagenstad, Christopher
    Spigel, David
    Marshall, John
    Cohn, Allen
    McCollum, David
    Stella, Philip
    Deeter, Robert
    Shahin, Seta
    Amado, Rafael G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) : 672 - 680
  • [7] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [9] PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck
    Wirth, Lori J.
    Dakhil, Shaker
    Kornek, Gabriela
    Axelrod, Rita
    Adkins, Douglas
    Pant, Shubham
    O'Brien, Paul
    Debruyne, Philip R.
    Oliner, Kelly S.
    Dong, Jun
    Murugappan, Swami
    [J]. ORAL ONCOLOGY, 2016, 61 : 31 - 40
  • [10] A Randomized Phase-IIIb Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared with Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
    Mross, Klaus
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 (09) : 617 - 618
12345